Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL E MANNING

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1396744249
CMS profile
335771
Location
SCOTTSDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$129,290.76

170 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL E MANNING

NPI 1396744249 · CMS profile ID 335771

Allopathic & Osteopathic Physicians / Allergy & Immunology

SCOTTSDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396744249?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL E MANNING, NPI 1396744249, CMS profile ID 335771. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396744249?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MICHAEL E MANNING, NPI 1396744249, CMS profile ID 335771. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396744249?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MICHAEL E MANNING, NPI 1396744249, CMS profile ID 335771, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 170 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1396744249?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

170 matching records · $129,290.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 170 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 170.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Pharming Healthcare, Inc. $2,000.0009/22/2020 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735546939 CMS
OptiNose US, Inc. $22.5009/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737146879 CMS
Pharming Healthcare, Inc. $5.5109/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735546937 CMS
Takeda Pharmaceuticals U.S.A., Inc. $30.1809/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747260791 CMS
Pharming Healthcare, Inc. $2,000.0009/16/2020 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735546935 CMS
GENZYME CORPORATION $23.0809/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744108459 CMS
Pharming Healthcare, Inc. $2,000.0009/09/2020 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735546933 CMS
AstraZeneca Pharmaceuticals LP $21.2209/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736342829 CMS
Regeneron Healthcare Solutions, Inc. $450.0008/25/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724437249 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.0608/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747260789 CMS
PFIZER INC. $28.7108/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743285337 CMS
BioCryst Pharmaceuticals, Inc. $2,375.0008/13/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749718007 CMS
GlaxoSmithKline, LLC. $1,200.0008/11/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738952165 CMS
Teva Pharmaceuticals USA, Inc. $11.1408/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749481657 CMS
OptiNose US, Inc. $12.9908/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737146869 CMS
AstraZeneca Pharmaceuticals LP $12.9108/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736368797 CMS
GENZYME CORPORATION $18.8608/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744108451 CMS
GlaxoSmithKline, LLC. $1,200.0007/28/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738752369 CMS
OptiNose US, Inc. $26.1207/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737146865 CMS
ADMA BioManufacturing LLC $15.5507/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750640643 CMS
CSL Behring $27.5007/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728954399 CMS
GlaxoSmithKline, LLC. $178.8307/22/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738757843 CMS
AstraZeneca Pharmaceuticals LP $750.0007/21/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736429829 CMS
GlaxoSmithKline, LLC. $31.7007/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738949941 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.8507/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747260787 CMS
PFIZER INC. $1,850.0007/10/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743813359 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.4807/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747260785 CMS
AstraZeneca Pharmaceuticals LP $25.4307/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736269825 CMS
AIMMUNE THERAPEUTICS, INC. $3,450.0007/03/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 731287025 CMS
AstraZeneca Pharmaceuticals LP $24.6206/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736345639 CMS
GlaxoSmithKline, LLC. $62.9906/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738600267 CMS
Pharming Healthcare, Inc. $6.7306/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735546931 CMS
PFIZER INC. $1,850.0006/29/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743813357 CMS
CSL Behring $27.3606/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728954413 CMS
AstraZeneca Pharmaceuticals LP $13.3506/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735926857 CMS
Eyevance Pharmaceuticals LLC $23.6606/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753064471 CMS
Eyevance Pharmaceuticals LLC $13.2906/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753064475 CMS
Regeneron Healthcare Solutions, Inc. $6.7606/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724437245 CMS
Pharming Healthcare, Inc. $4,500.0006/10/2020 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735546929 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,237.5006/10/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747260783 CMS
AstraZeneca Pharmaceuticals LP $16.7306/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736272703 CMS
GENZYME CORPORATION $20.3305/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744108419 CMS
CSL Behring $21.1505/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728954273 CMS
Teva Pharmaceuticals USA, Inc. $12.9905/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749486043 CMS
BioCryst Pharmaceuticals, Inc. $2,750.0005/09/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749717523 CMS
CSL Behring $1,410.0005/08/2020 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728954283 CMS
Pharming Healthcare, Inc. $5,200.0005/08/2020 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735546927 CMS
AstraZeneca Pharmaceuticals LP $16.1805/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735999987 CMS
AstraZeneca Pharmaceuticals LP $24.7005/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735973457 CMS
GlaxoSmithKline, LLC. $2,400.0005/05/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738492553 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $215,456.14 319
PY2020 $129,290.76 170
PY2021 $133,415.04 194
PY2022 $118,005.18 230
PY2023 $150,893.11 297
PY2024 $149,197.00 265
PY2025 $183,947.01 304

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $35,012.73 31
PY2025 Principal investigator $71,701.26 184
PY2024 Principal investigator $219,912.00 272
PY2023 Recipient $187.86 1
PY2023 Principal investigator $266,648.88 344
PY2022 Principal investigator $244,963.26 250
PY2021 Principal investigator $790,224.20 333
PY2020 Principal investigator $320,445.15 137
PY2019 Principal investigator $223,432.68 70

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

215 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ionis Pharmaceuticals, Inc. $65.00 12/30/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246791996
Principal investigator 1 Ionis Pharmaceuticals, Inc. $77.00 12/30/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246792001
Principal investigator 1 Ionis Pharmaceuticals, Inc. $97.50 12/30/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246792006
Principal investigator 1 Ionis Pharmaceuticals, Inc. $150.00 12/30/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246792009
Principal investigator 1 Ionis Pharmaceuticals, Inc. $200.00 12/30/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246792013
Principal investigator 1 Ionis Pharmaceuticals, Inc. $250.00 12/30/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246792016
Principal investigator 1 Ionis Pharmaceuticals, Inc. $260.00 12/30/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246792019
Principal investigator 1 Ionis Pharmaceuticals, Inc. $292.50 12/30/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246792023
Principal investigator 1 Ionis Pharmaceuticals, Inc. $325.00 12/30/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246792027
Principal investigator 1 Ionis Pharmaceuticals, Inc. $400.00 12/30/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246792031
Principal investigator 1 Ionis Pharmaceuticals, Inc. $100.00 12/30/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246792035
Principal investigator 1 Ionis Pharmaceuticals, Inc. $231.00 12/30/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246792038
Principal investigator 1 Ionis Pharmaceuticals, Inc. $300.00 12/30/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246792042
Principal investigator 1 Ionis Pharmaceuticals, Inc. $800.00 12/30/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246792045
Recipient CSL Behring $50.00 12/22/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664255
Recipient CSL Behring $135.00 12/22/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664257
Recipient CSL Behring $350.00 12/22/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664259
Recipient CSL Behring $391.00 12/15/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664253
Principal investigator 1 GlaxoSmithKline, LLC. $4,614.14 12/03/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN No dispute reported 06/30/2026 1192167719
Recipient CSL Behring $50.00 11/17/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664249
Recipient CSL Behring $405.00 11/17/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $623.69 11/17/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184261591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $623.69 11/03/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184257037
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,000.00 10/23/2025 Non-covered Recipient Entity
ALLERGY ASTHMA IMMUNOLOGY ASSOCIA LTD
A 52-week multicenter, randomized, double-blind, placebo-controlled study to assess efficacy and safety of remibrutinib (LOU064) in adult and adolescent participants with IgE-mediated food allergy. No dispute reported 06/30/2026 1190309082
Recipient CSL Behring $1,688.00 10/22/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $136.00 10/15/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184250113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 10/15/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184250115
Principal investigator 1 SANOFI US SERVICES INC. $3,600.00 10/14/2025 Non-covered Recipient Entity
Allergy, Asthma And Immunology Associates, Ltd
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226091530
Recipient CSL Behring $1,079.73 10/02/2025 Covered Recipient Physician Garadacimab Real-world Treatment Outcomes of Effectiveness, Safety, and Quality-of-Life in Patients With HAE (GREAT Study) No dispute reported 06/30/2026 1252664245
Principal investigator 1 Ionis Pharmaceuticals, Inc. $250.00 09/19/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246787503
Principal investigator 1 Ionis Pharmaceuticals, Inc. $300.00 09/19/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246787507
Principal investigator 1 Ionis Pharmaceuticals, Inc. $500.00 09/19/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246787510
Principal investigator 1 Ionis Pharmaceuticals, Inc. $600.00 09/19/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246787514
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,200.00 09/19/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246787518
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,000.00 09/19/2025 Non-covered Recipient Entity
ONE OF A KIND CLINICAL RESEARCH CENTER LLC
IS744CS7 No dispute reported 06/30/2026 1246787522
Recipient CSL Behring $3,439.00 09/15/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664243
Principal investigator 1 CSL Behring $212.67 09/15/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673376
Recipient CSL Behring $5,000.00 09/10/2025 Covered Recipient Physician Garadacimab Real-world Treatment Outcomes of Effectiveness, Safety, and Quality-of-Life in Patients With HAE (GREAT Study) No dispute reported 06/30/2026 1252664239
Recipient CSL Behring $4,500.00 09/10/2025 Covered Recipient Physician Garadacimab Real-world Treatment Outcomes of Effectiveness, Safety, and Quality-of-Life in Patients With HAE (GREAT Study) No dispute reported 06/30/2026 1252664241
Principal investigator 1 GlaxoSmithKline, LLC. $2,020.00 08/22/2025 Non-covered Recipient Entity
ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES LTD
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192167715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 08/21/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184229283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38.75 08/21/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184229285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 08/21/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184229291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 08/21/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184229531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 08/21/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184229537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 08/21/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184229539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.50 08/21/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184229541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $46.25 08/21/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184229559
Principal investigator 1 CSL Behring $220.13 08/11/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673348
Principal investigator 1 CSL Behring $42.73 08/11/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673350
Principal investigator 1 CSL Behring $105.60 08/11/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673352
Principal investigator 1 CSL Behring $373.01 08/11/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673354
Principal investigator 1 CSL Behring $315.68 08/11/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673356
Principal investigator 1 CSL Behring $450.00 08/11/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673358
Principal investigator 1 CSL Behring $643.66 08/11/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673360
Principal investigator 1 CSL Behring $760.56 08/11/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673362
Principal investigator 1 CSL Behring $448.84 08/11/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673364
Principal investigator 1 CSL Behring $42.73 08/11/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673366
Principal investigator 1 CSL Behring $261.12 08/01/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673188
Principal investigator 1 GlaxoSmithKline, LLC. $1,319.00 07/23/2025 Non-covered Recipient Entity
ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES LTD
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192167695
Principal investigator 1 SANOFI US SERVICES INC. $475.00 07/14/2025 Non-covered Recipient Entity
Allergy, Asthma And Immunology Associates, Ltd
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226091508
Principal investigator 1 GlaxoSmithKline, LLC. $1,765.00 07/02/2025 Non-covered Recipient Entity
ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES LTD
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192165569
Principal investigator 1 GlaxoSmithKline, LLC. $2,030.00 07/02/2025 Non-covered Recipient Entity
ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES LTD
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192167707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $479.06 07/02/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184212605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $623.69 06/30/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184212107
Principal investigator 1 CSL Behring $220.13 06/12/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673332
Principal investigator 1 CSL Behring $42.73 06/12/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673334
Principal investigator 1 CSL Behring $105.60 06/12/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673336
Principal investigator 1 CSL Behring $373.01 06/12/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673338
Principal investigator 1 CSL Behring $315.68 06/12/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673340
Principal investigator 1 CSL Behring $3,600.00 06/12/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673342
Principal investigator 1 CSL Behring $450.00 06/12/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673344
Principal investigator 1 CSL Behring $85.46 06/12/2025 Non-covered Recipient Entity
Allergy Asthma and Immunology Associates South Scottsdale Office
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252673346
Principal investigator 1 CSL Behring $962.22 06/11/2025 Non-covered Recipient Entity
VA Minneapolis health care
An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-nave Subjects With Primary Immunodeficiency No dispute reported 06/30/2026 1252670126
Principal investigator 1 GlaxoSmithKline, LLC. $417.00 06/06/2025 Non-covered Recipient Entity
ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES LTD
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192167699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $122.50 06/04/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184202949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 06/04/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184202977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $187.50 06/04/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184202981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/04/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184203381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/04/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184203403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/04/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184203407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/04/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184203419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/04/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184203441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 06/04/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184203463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 06/04/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184203681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $952.00 06/04/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184203761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $43.75 06/04/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184203829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 06/04/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184203837
Recipient CSL Behring $50.00 06/02/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664233
Recipient CSL Behring $135.00 06/02/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664235
Recipient CSL Behring $400.00 06/02/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664237
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 06/02/2025 Non-covered Recipient Entity
ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES LTD
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192167703
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 05/27/2025 Non-covered Recipient Entity
Allergy, Asthma And Immunology Associates, Ltd
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226091501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $623.69 05/19/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184196349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 05/14/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184194509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 05/14/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184194511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 05/14/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184194513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 05/14/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184194515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 05/14/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184194517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 05/14/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184194519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $46.25 05/14/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184194521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 05/14/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184194523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38.75 05/14/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184194525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.50 05/14/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184194527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38.75 05/14/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184194529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.50 05/07/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 05/07/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 05/07/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38.75 05/07/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 05/07/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38.75 05/07/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 05/07/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 05/07/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $46.25 05/07/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 05/07/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184192929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $479.06 04/28/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $623.69 04/23/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184187993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/18/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184185041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $48.75 04/18/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184185043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/18/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184185045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 04/18/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184185047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/18/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184185049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $122.50 04/18/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184185051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $43.75 04/18/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184185053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $187.50 04/18/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184185055
Recipient CSL Behring $1,751.00 04/11/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664231
Principal investigator 1 SANOFI US SERVICES INC. $4,258.00 04/02/2025 Non-covered Recipient Entity
Allergy, Asthma And Immunology Associates, Ltd
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226091497
Recipient CSL Behring $50.00 03/17/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664223
Recipient CSL Behring $400.00 03/17/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664225
Recipient CSL Behring $950.00 03/17/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664227
Recipient CSL Behring $2,004.00 03/17/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664229
Recipient CSL Behring $50.00 03/07/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252664211
Recipient CSL Behring $185.00 03/07/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252664213
Recipient CSL Behring $400.00 03/07/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252664215
Recipient CSL Behring $665.00 03/07/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252664217
Recipient CSL Behring $1,300.00 03/07/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252664219
Recipient CSL Behring $1,500.00 03/07/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252664221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $623.69 02/27/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184155830
Principal investigator 1 GlaxoSmithKline, LLC. $956.70 02/25/2025 Non-covered Recipient Entity
ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES LTD
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192167689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38.75 02/20/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184154726
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 02/20/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184154728
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 02/20/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184154730
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 02/20/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184154732
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $46.25 02/20/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184154734
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.50 02/20/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184154736
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 02/20/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184154738
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 02/20/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184154740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 02/20/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184154742
Recipient CSL Behring $5,317.00 02/19/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.50 02/13/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184153898
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 02/13/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184153900
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 02/13/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184153902
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $46.25 02/13/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184153904
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 02/13/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184153906
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 02/13/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184153908
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38.75 02/13/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184153910
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 02/13/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184153912
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38.75 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $46.25 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38.75 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.50 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184151999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38.75 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184152021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184152386
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184152394
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38.75 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184152398
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184152402
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184152408
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184152410
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $52.50 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184152414
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38.75 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184152416
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184152418
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $46.25 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184152420
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27.50 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184152422
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38.75 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184152424
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.00 02/05/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184152426
Principal investigator 1 SANOFI US SERVICES INC. $2,565.00 02/04/2025 Non-covered Recipient Entity
Allergy, Asthma And Immunology Associates, Ltd
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226091492
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $479.06 01/31/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184151549
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,186.76 01/28/2025 Non-covered Recipient Entity
MANNINGS 8TH AVENUE, INC
A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy No dispute reported 06/30/2026 1190301621
Principal investigator 1 GlaxoSmithKline, LLC. $1,647.00 01/24/2025 Non-covered Recipient Entity
ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES LTD
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192165573
Recipient CSL Behring $1,783.00 01/17/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664207
Recipient CSL Behring $100.00 01/15/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664199
Recipient CSL Behring $135.00 01/15/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664201
Recipient CSL Behring $350.00 01/15/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664203
Recipient CSL Behring $400.00 01/15/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 01/09/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184147425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $187.50 01/09/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184147427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 01/09/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184147429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 01/09/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184147431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $48.75 01/09/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184147433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 01/09/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184147435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 01/09/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184147437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 01/09/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184147439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 01/09/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184147441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 01/09/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184147443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 01/09/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184147445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $43.75 01/09/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184147447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 01/09/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184147449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $623.69 01/02/2025 Non-covered Recipient Entity
ALLERGY ASTHAMA AND IMMUNOLOGY ASSOCIATES LTD
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184144676
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,027.34 01/01/2025 Non-covered Recipient Entity
ALLERGY ASTHMA AND IMMUNOLOGY ASSOCIATES, LTD.
A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy No dispute reported 06/30/2026 1190309064